{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-040503","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.269276+00:00","generated_at":"2026-06-04T06:03:19.535130+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunome posts FY2023 net loss of $106.8M; cash $138.1M, AL102 Phase 3 data due Q1 2025","bullets":["Net loss $106.8M ($5.38 per share) for FY2023; cash and equivalents $138.1M as of Dec 31, 2023 (prior to Feb 2024 $230M offering).","AL102 Phase 3 RINGSIDE topline data expected Q1 2025; IND filings for IM-1021 and IM-3050 expected Q1 2025.","Closed acquisition of AL102 from Ayala (Mar 2024) and licensed IM-1021 from Zentalis (Jan 2024).","Completed $230M underwritten offering in Feb 2024, extending cash runway into 2026.","R&D expenses $23.1M, IPR&D $80.8M, G&A $19.7M for FY2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-040503","json":"https://secwatch.observer/filing/0001104659-24-040503.json","markdown":"https://secwatch.observer/filing/0001104659-24-040503.md","text":"https://secwatch.observer/filing/0001104659-24-040503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924040503/0001104659-24-040503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924040503/tm2410047d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:03:19.535130+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7e183344a7d6400f0c6bcc78b686bf36f6e0bc5f","claim":"Immunome Inc. reported the full-year ended December 31, 2023 results: net income $106.8 million, EPS $5.38.","evidence_excerpt":"Immunome reported a net loss of $106.8 million, or basic and diluted net loss per share attributable to common stockholders of $5.38, for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924040503/0001104659-24-040503-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full-year ended December 31, 2023"},{"label":"Net income","value":"$106.8 million"},{"label":"EPS","value":"$5.38"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}